February 18, 2025

The Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market is driven by rising prevalence of chronic diseases

The global autologous stem cell and non-stem cell based therapies market offers a wide range of treatment options which involves the use stem cells and tissues from patient’s own body to treat chronic diseases and disorders. Autologous stem cell therapies help regenerate damaged cells, tissues and organs and help treat conditions like cardiovascular diseases, neurological disorders, orthopedic and musculoskeletal disorders. Non-stem cell based therapies include platelet rich plasma injections which contains high concentration of growth factors to speed up the healing of damaged tissues. The demand for autologous stem cell and non-stem cell based therapies is increasing among patients as they provide minimally invasive treatment option with fewer side effects compared to traditional medicines and surgeries.

The global Autologous Stem Cell and Non-Stem Cell Based Therapies Market is estimated to be valued at US$ 98.8 Bn in 2023 and is expected to exhibit a CAGR of 0.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
One of the key trends in the autologous stem cell and non-stem cell based therapies market is the growing adoption of adipose tissue-derived stem cells. Adipose tissue is an abundant and accessible source of adult stem cells that can be easily obtained from liposuction or lipectomy procedures. Adipose derived stem cells have strong therapeutic potential and regenerative abilities similar to bone marrow derived stem cells. Researchers are exploring their application in treatment of diseases like critical limb ischemia, intervertebral disc degeneration, joint disorders and more. This has boosted the demand for adipose tissue-derived stem cell therapies over the forecast period.

Porter’s Analysis

Threat of new entrants: Low barriers to entry as the market is still developing. Regulations around stem cell therapy may deter new players from entering.

Bargaining power of buyers: Buyers have moderate bargaining power as there are several autologous stem cell therapy providers. The unique needs of each patient also makes switching difficult.

Bargaining power of suppliers: Suppliers have high bargaining power as sourcing of raw material like stem cells is specialized. Suppliers can control supply and demand.

Threat of new substitutes: Low threat as autologous stem cell therapy has limited substitutes currently for treatment of various conditions. Advancements may introduce new substitutes.

Competitive rivalry: High competition among providers developing new treatment approaches. Companies compete based on clinical research programs, strategic partnerships and collaborations.

Key Takeaways

The global Autologous Stem Cell and Non-Stem Cell Based Therapies market is expected to witness high growth. The global Autologous Stem Cell and Non-Stem Cell Based Therapies Market is estimated to be valued at US$ 98.8 Bn in 2023 and is expected to exhibit a CAGR of 0.0% over the forecast period 2023 to 2030.

North America is anticipated to be the dominant as well as the fastest growing regional market due to supportive reimbursement policies and rising focus on research and development activities in the region.

Europe is also a promising market fueled by increased healthcare spending and rising awareness regarding autologous stem cell therapies. Asia Pacific market is expected to grow at a high rate driven by growing economy, rising medical tourism and increasing focus of international players on establishing manufacturing and research facilities in the region.

Key players operating in the Autologous Stem Cell and Non-Stem Cell Based Therapies market are Caladrius Biosciences, Vericel Corporation, Fibrocell Science, Inc., Genzyme Corporation, BrainStorm Cell Therapeutics, Regeneus Ltd., and Dendreon Corporation. The players are focused on expanding their clinical research portfolio and bringing new therapies to the market through strategic collaborations.

*Note:

  1. Source: Coherent Market Insights, Public sources, Desk research
  2. We have leveraged AI tools to mine information and compile it

Money Singh

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc.

View all posts by Money Singh →